Paper Details

  1. Home
  2. Paper Details

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.

Author: BorthakurGautam, CleelandCharles, CortesJorge E, EstrovZeev, Garcia-ManeroGuillermo, GeorgeBinsah, JabbourElias, KadiaTapan, KantarjianHagop, LinHuei-Kan, O'BrienSusan, RavandiFarhad, ShiQiuling, WierdaWilliam, WilliamsLoretta A, Zulbaran-RojasAlejandro

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Side effects related to TKIs may impact the quality of life in patients with CML-CP. Further studies should investigate factors associated with these symptoms and interventions that may improve the patients' QoL.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment with tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) is effective but needs to continue for several years, possibly indefinitely. Although generally safe, TKI may have hitherto poorly recognized effects in the quality of life (QoL) of such pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246941/

データ提供：米国国立医学図書館（NLM）

The Quality of Life in CML Treatment: Navigating the Desert of Side Effects

Chronic myeloid leukemia (CML) is a challenging condition, a desert of uncertainty for those affected. This study focuses on the quality of life (QoL) of patients with CML treated with tyrosine kinase inhibitors (TKIs), a class of drugs that effectively target the disease. The researchers investigated the symptom burden experienced by these patients, shedding light on the potential side effects of TKI therapy.

TKI Treatment: Finding Balance in the Desert of Side Effects

The study reveals that while TKIs effectively manage CML, they can lead to persistent symptoms, primarily fatigue, impacting patients' QoL. Despite achieving deep molecular remission, many patients experience persistent mild symptoms, highlighting the need for ongoing efforts to mitigate these side effects and improve patient well-being. The authors emphasize the importance of a comprehensive approach to managing CML, encompassing not only disease control but also patient QoL.

Navigating the CML Desert: Minimizing Side Effects and Maximizing QoL

This research underscores the importance of addressing the QoL concerns of patients with CML undergoing TKI therapy. The study provides valuable insights into the symptom burden experienced by these patients, highlighting the need for strategies to minimize these side effects and enhance their overall well-being. This research is a reminder that effective treatment goes beyond disease control, encompassing the holistic needs of the patient.

Dr.Camel's Conclusion

The study of symptom burden in CML patients undergoing TKI treatment is like navigating a desert of side effects, seeking to minimize their impact on QoL. The research reveals the importance of addressing these symptoms, emphasizing the need for a multi-faceted approach to managing CML, encompassing both disease control and patient well-being. This study is a valuable reminder that effective treatment is not just about achieving remission, but also about ensuring the overall health and happiness of those affected by this challenging condition.

Date :
  1. Date Completed 2019-11-14
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

30318751

DOI: Digital Object Identifier

PMC6246941

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.